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Aims/hypothesis. Data now indicate that proinsulin C-peptide exerts important physiological eﬀects and shows the characteristics
of an endogenous peptide hormone. This study aimed to investigate the inﬂuence of C-peptide and fragments thereof on
erythrocyte deformability and to elucidate the relevant signal transduction pathway. Methods. Blood samples from 23 patients
with type 1 diabetes and 15 matched healthy controls were incubated with 6.6nM of either human C-peptide, C-terminal
hexapeptide, C-terminal pentapeptide, a middle fragment comprising residues 11–19 of C-peptide, or randomly scrambled C-
peptide. Furthermore, red blood cells from 7 patients were incubated with C-peptide, penta- and hexapeptides with/without
addition of ouabain, EDTA, or pertussis toxin. Erythrocyte deformability was measured using a laser diﬀractoscope in the shear
stressrange0.3–60Pa.Results.Erythrocytedeformabilitywasimpairedby18–25%intype1diabeticpatientscomparedtomatched
controls in the physiological shear stress range 0.6–12Pa (P<. 01–.001). C-peptide, penta- and hexapeptide all signiﬁcantly
improved the impaired erythrocyte deformability of type 1 diabetic patients, while the middle fragment and scrambled C-
peptide had no detectable eﬀect. Treatment of erythrocytes with ouabain or EDTA completely abolished the C-peptide, penta-
and hexapeptide eﬀects. Pertussis toxin in itself signiﬁcantly increased erythrocyte deformability. Conclusion/interpretation.C -
peptide and its C-terminal fragments are equally eﬀective in improving erythrocyte deformability in type 1 diabetes. The C-
terminal residues of C-peptide are causally involved in this eﬀect. The signal transduction pathway is Ca
2+-dependent and involves
activation of red blood cell Na
+,K
+-ATPase.
Copyright © 2008 Thomas Hach et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
During the past decade, several studies have provided
evidence that C-peptide is a biologically active endogenous
peptide. It binds speciﬁcally in nanomolar concentration
to cell membranes [1], possibly to a G-protein-coupled
receptor, resulting in internalisationof the peptide [2]a n d
activation of Ca2+- and MAPK-dependent signalling path-
ways [3–6]. Cellular end-eﬀects include stimulation and
induction of both Na+,K +- A T P a s e ,a n de N O Sa sw e l la s
activation of a series of transcriptional fators [3, 7–10].
Studies in patients with type 1 diabetes who lack endoge-
nous C-peptide production show that administration of C-
peptide in replacement doses results in increased regional
blood ﬂow in several tissues [11–13] and amelioration of
diabetes-induced functional and structural abnormalities of
the peripheral nerves and the kidneys [14–16]. Not only
the full-length native C-peptide but also its C-terminal
pentapeptide fragment is reported to exert physiological
eﬀects [1, 4, 6, 17, 18].
It is well established that diabetes is associated with
reduced deformability of red blood cells [19–21]. This
abnormality is of clinical signiﬁcance in that it compromises
the ability of red blood cells to pass through capillaries,
reduces tissue perfusion, and impairs tissue oxygen supply
[4, 22]. The mechanism underlying the decreased red cell
compliance in diabetes is not well understood, but it has
been shown that C-peptide is capable of restoring red cell
deformability to normal levels, most likely via stimulation
of red cell Na+,K +-ATPase [23]. The extent to which2 Experimental Diabetes Research
Table 1: Clinical characteristics of study subjects.
Healthy controls n = 15 Type 1 diabetes patients n = 23
Sex (male/female) 8/7 13/10
Age (years) 34 ± 43 6 ± 3
Height (m) 1.76 ±0.02 1.75 ±0.02
Weight (kg) 78.0 ±2.87 7 .5 ±2.6
Diabetes duration (years) 0 ± 02 4 ± 3
Serum glucose (mmol/L) 4.94 ±0.22 7.44 ±0.67
HbA1c (%) 5.7 ±0.37 .3 ±0.2
Serum C-peptide (nmol/L) 0.77 ±0.09 0.01 ±0.003
Table 2: Amino acid structure of C-peptide and C-peptide fragments used in this study.
Amino acid structure Position
C-Peptide EAEDLQVGQVELGGGPGAGSLQPLALEGSLQ (1–31)
MF ELGGGPGAG (11–19)
HP LEGSLQ (26–31)
PP EGSLQ (27–31)
C-peptide fragments will do the same has not been deter-
mined. Consequently, the aim of this study was to examine
the inﬂuence of C-peptide and its C-terminal fragments, as
well as middle segments on the abnormal deformability of
red blood cells from type 1 diabetes patients. In addition,
aspects of a possible signal transduction pathway were
evaluated.
2. SUBJECTS, MATERIALS, AND METHODS
2.1. Subjects
Blood samples were taken from 23 type 1 diabetes patients
and 15 matched healthy controls (Table 1). Inclusion criteria
were C-peptide serum level < 0.2nmol/L, diabetes duration
> 2 years, serum creatinine < 2mg/dL, and no clinically rel-
evant diabetic long-term complications. Hematocrit values
were in the normal range for all patients and controls.
2.2. Materialsandmethods
Laser diﬀractoscopy was performed using a Rheodyn SSD
shear stress diﬀractometer (Myrenne GmbH, Roetgen,
Germany). The method of laser diﬀractoscopy has been
d e s c r i b e di nd e t a i lp r e v i o u s l y[ 21, 23]. In summary, a He-
Ne-Laser detects deformation of erythrocytes between two
parallel glass discs, one of which rotates resulting in deﬁned
shear stresses as per the following equation:
τ =
2πr·η
t·h
,( 1 )
where τ= shear stress, r = laser beam distance from rotation
center, η = viscosity, h = height of gap between discs, and
t = time.
Adjustingforequipment-speciﬁcvalues(r =25mm,h =
0.5mm, and η = 24mPa), the equation is condensed to
τ = 7.536Pa·rpm, (2)
where rpm = revolutions per minute.
The applied shear stress range is electronically regulated
and includes 8 levels (0.3 Pa; 0.6 Pa; 1.2 Pa; 3 Pa; 6 Pa; 12 Pa;
30Pa; 60Pa).
The erythrocyte deformability measurement detects
scattered-light intensities along orthogonal axes (A, B) of
red blood cells within the laser diﬀraction light cone.
The erythrocyte elongation index (EI) is calculated by the
following equation:
EI(%) =

A −B
A+B

·100. (3)
Allexperimentswerecarriedoutat23◦C,whichwasther-
mostatically regulated. Blood samples were collected using
ammonium-heparinated vials and subsequently distributed
to dextran medium (30μL blood per 2mL dextran). Stability
tests were performed to exclude signiﬁcant eﬀects of storage
time and/or serum glucose concentration on erythrocyte
deformability measured by laser diﬀractoscopy (data not
shown). All measurementsoferythrocyte deformability were
carried out before incubation with active ingredients as well
as at 1, 30, and 60 minutes after incubation
C-peptideandC-peptidefragments
Human C-peptide and all C-peptide fragments were pro-
vided by Creative Peptides (Stockholm, Sweden) at a purity
of >98%. C-peptide and its fragments were dissolved in
phosphate buﬀer and incubations were made at 6.6nmol/L.
The incubation and mixing of probes were done smoothly toThomas Hach et al. 3
avoid external shear stress. The fragments used in this study
were C-terminal hexapeptide, C-terminal pentapeptide, a
middle fragment including residues 11–19, and randomly
scrambled C-peptide; their amino acid sequences are pre-
sented in Table 2.
Ouabain
Ouabain was obtained from Sigma-Aldrich (St. Louis, Mo,
USA). Treatment with ouabain was titrated to achieve a
concentration of 1μmol/L. Incubations with and without C-
peptide or fragments lasted 30 minutes at 23◦C.
EDTA
Incubations with EDTA (1.6mg/mL) with and without C-
peptide or fragments lasted 30 minutes at 23◦C. Treatment
with EDTA alone did not alter erythrocyte deformability
(data not shown).
Pertussistoxin
Pertussis toxin was obtained from Sigma-Aldrich. Treatment
with pertussis toxin (1μg/mL) was conducted for 60 minutes
at 37◦C.
Statisticalanalysis
Results are expressed as the means ± SD. Gaussian dis-
tribution was checked by the Kolmogoroﬀ-Smirnoﬀ test.
Statistical analysis were done by two-site ANOVA and
Student’s t test. A P-value of less than .05 was regarded as
statistically signiﬁcant.
3. RESULTS
Erythrocytedeformabilitywassigniﬁcantlydecreasedintype
1 diabetes patients compared to healthy controls over the
full range of shear stress tested (Figure 1). In the physio-
logical shear stress range (≤12Pa), the diﬀerence between
diabetic patients and healthy controls amounted to 18–25%
(P<. 01–.001). Incubation of the red cells from type 1
diabetes patients with C-peptide completely normalized the
erythrocyte defortmability at all tested shear stress levels
(Table 3). Incubation with the penta- and hexapeptides
also resulted in signiﬁcant improvements in erythrocyte
deformability over the range of shear stress tested; the
responses to C-peptide and the C-terminal peptides were
similar and there were no statistically signiﬁcant diﬀerences
between these three treatment groups. In contrast, the
middlefragmentexertednosigniﬁcanteﬀectonthediabetes-
induced abnormal erythrocyte deformability. Likewise and
as expected, scrambled C-peptide with a random amino acid
sequence had no beneﬁcial eﬀect on erythrocyte deformabil-
ity.
Pretreatment of erythrocytes from patients with type 1
diabetes with ouabain or EDTA completely abolished the
C-peptide-, penta- and hexapeptide-induced improvements
in deformability as shown in Figure 2 for the pentapeptide
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Figure 1: Erythrocyte elongation index (EI) (%) ± SD for
erythrocytes from healthy controls (open columns) and type 1
diabetes patients (ﬁlled columns) at diﬀerent levels of shear stress.
∗P<. 05. ∗∗P<. 01. ∗∗∗P<. 001 versus controls.
at the shear stress 1.2Pa. Similar results were obtained for
all levels of shear stress. Pretreatment of erythrocytes with
pertussis toxin in itself increased erythrocyte deformability
signiﬁcantly (P<. 05) in the shear stress range of 0.6–12Pa.
Therefore, the possible inﬂuence of G-protein inactivation
on the eﬀects mediated by C-peptide and its fragments could
not be evaluated.
4. DISCUSSION
The present results conﬁrm and extend previous obser-
vations indicating that red blood cell deformability is
compromised in diabetes [19–21] and that this abnormality
can be corrected by C-peptide [23]. Thus, using whole
blood samples and laser diﬀractoscopy, a method with
high reproducibility (CV < 1%), erythrocyte deformability
measured in blood samples from type 1 diabetes patients was
found to be reduced by 18–25% over the physiological shear
stress range (0.6–12Pa), in keeping with previous results
using the same methodology [23]. Exposing blood cells from
the diabetic patients to 6.6nM, C-peptide was found to fully
normalize membrane deformability. We now show that not
only the native, full length C-peptide but also its C-terminal
penta-andhexapeptidespossessthiscapability.Incontrast,a
middle segment comprising residues 11–19 of C-peptide had
no eﬀect. The speciﬁcity of the observed eﬀects is attested by
the ﬁnding that scrambled C-peptide, a control peptide with
its residues assembled in random order, had no detectable
eﬀect.
The current results for the pentapeptide are in line
with previous reports that it competes with C-peptide for
cellular binding [1], that it elicits an increase in intra-
cellular Ca2+-concentration [4], activates PKC isoforms,
causes phosphorylation of ERK1/2 and JNK, and stimulates
Na+,K +-ATPase activity [6, 17, 24]. Studies evaluating the
pentapeptide’s cellular binding/competition characteristics,
its stimulatory eﬀect on intracellular Ca2+-concentrations
and ERK1/2 phosphorylation demonstrate that it is the
N-terminal Glu-residue of the pentapeptide (Glu 27 of4 Experimental Diabetes Research
Table 3: Erythrocyte elongation index (EI) (%) in the shear stress range 0.6–12 Pa for diﬀerent treatment groups, n = 23.
Shear stress
0.6 Pa 1.2 Pa 3 Pa 6 Pa 12 Pa
Healthy controls 5.87 ±0.72
∗ 14.37 ±0.61
∗ 29.08 ±0.79
∗ 39.19 ±1.02
∗ 45.93 ±0.85
∗
Diabetes patients 4.38 ±0.63 11.77 ± 0.49 26.01 ±0.60 35.48 ±0.84 43.34 ±0.92
C-peptide 5.40 ±0.82
∗ 14.11 ±0.85
∗ 28.34 ±1.58
∗ 39.07 ±1.46
∗ 45.82 ±1.43
∗
HP 5.77 ±0.81
∗ 14.18 ±1.17
∗ 28.61 ±1.37
∗ 38.49 ±1.62
∗ 45.82 ±1.81
∗
PP 6.12 ±0.93
∗ 14.02 ±1.37
∗ 28.23 ±1.46
∗ 38.85 ±1.54
∗ 45.20 ±1.74
∗
MF 4.42 ±0.89 11.39 ± 1.07 25.82 ±1.24 35.79 ±0.98 43.39 ±1.17
SCR 4.10 ±0.91 11.25 ± 1.07 25.58 ±1.07 35.64 ±0.91 43.48 ±1.00
∗P<. 01versus type 1 diabetes patients.
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Figure 2: Erythrocyte elongation index (EI) (%) ± SD for
erythrocytesfromhealthycontrolsandtype1diabetespatients.The
latter cells were incubated with C-peptide, hexapeptide (HP), and
pentapeptide (PP) from the C-terminal region of C-peptide as well
as a middle fragment (MF) and scrambled peptide (SCR, control).
Results for combined incubation with PP and oubain or EDTA
are also shown. Data are obtained at the shear stress level 1.2Pa.
∗∗∗P<. 001 versus untreated erythrocytes from type 1 diabetes
patients.
C-peptide) that is of primary importance for its bioactivity;
alanine substitution of the other four residues has little or
no eﬀect on the pentapeptide’s bioactivity [4, 25, 26]. Its
bioactivity has been found to be similar to that of the native
peptide both in the above in vitro studies and in invivo
experiments evaluating its stimulatory eﬀect on whole-
body glucose utilization [18] and its inhibition of diabetes-
induced glomerular hyperﬁltration [27] in streptozotocin-
diabetic rats.
The C-terminal hexapeptide was found to be equally
potent as the pentapeptide and the native C-peptide with
regard to its amelioration of diabetes-induced abnormal red
blood cell deformability (Figure 2). Only little information is
availablewithregardtothephysiologyofthehexapeptidebut
the current ﬁndings are in line with previous observations
that it is capable of stimulating Na+,K +-ATPase in renal
tubular segments with potency similar to that of the
pentapeptide [17]. In contrast to the ﬁndings for the two C-
terminal segments, there was no indication that the middle
fragment (residues 11–19) exerted a measurable eﬀect on
diabetes-induced abnormal red cell deformability. Variable
results have been reported previously for middle fragments;
mildstimulationofNa+,K +-ATPaseinrenaltubulesegments
[17]b u tn oe ﬀect on glucose utilization under in vivo
conditions [18]h a v eb e e no b s e r v e d .
Exposing red blood cells from patients with type 1
diabetes to either oubain or EDTA resulted in complete
abrogation of the normalizing eﬀect by the penta- and
hexapeptides or C-peptide on erythrocyte deformability.
Evaluation of a G-protein involvement in the signalling
pathway could not be carried out since exposure of the
erythrocytes to pertussis toxin in itself resulted in alteration
of red cell deformability in contrast to previous ﬁndings for
rabbit erythrocytes [28]. Nevertheless, the results indicate
that the beneﬁcial eﬀects of the peptides are mediated
v i aaC a 2+-dependent stimulation of erythrocyte Na+,K +-
ATPase, in analogy with the previously established signal
transduction pathway for C-peptide and Na+,K +-ATPase in
humanrenaltubularcells[24],eventhoughtheEDTAresults
may suggest that other metal ions also are of importance for
the signal transduction [29].
ExposureoferythrocytestoC-peptide anditsC-terminal
fragments is thus likely to result in augmented generation
and release of ATP, as has been observed directly in the
case of C-peptide and both normal and diabetic red blood
cells [29]. ATP is a recognized stimulus of nitric oxide
synthase of platelets and erythrocytes [30, 31]. Nitric oxide,
besides being a potent vasodilator, is also eﬀective in
eliciting improved red blood cell deformability as a result of
direct action of nitric oxide on the erythrocyte membrane
[32, 33]. In addition, C-peptide-related improvement of red
cell deformability may be mediated not via ATP but by
direct stimulation of red cell nitric oxide synthase. TheThomas Hach et al. 5
latter is functionally similar to that of endothelial cells
[31], and C-peptide and most likely also its C-terminal
fragments are known to stimulate and cause induction
of endothelial nitric oxide synthase [8, 10]. The above
mechanisms are likely to contribute to the maintenance of
normal erythrocyte membrane plasticity and the extent to
which they are modiﬁed in diabetes is unknown. However,
irrespective of the exact mechanism involved, the present
ﬁndings demonstrate that both C-peptide and its C-terminal
fragmentsarecapableofeﬀectivelynormalizingthediabetes-
induced reduction in red blood cell deformability. It is
probable that this eﬀect contributed importantly to the
observed improvement in regional blood ﬂow of skin, mus-
cle, myocardium, and peripheral nerve in animals and type
1 diabetes patients, following administration of C-peptide
to physiological concentrations [11–13, 34]. Furthermore,
the beneﬁcial clinical eﬀects of C-peptide on early-stage
neuropathy [14] and nephropathy [15] in type 1 diabetes
may in part be related to correction of the abnormal red cell
deformability and subsequently improved microcirculation.
Further clinical trials are warranted document and deﬁne
the role of C-peptide and its C-terminal fragments in the
treatment and/or prevention of microvascular complications
of type 1 diabetes.
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